References
- World Health Organization (WHO)World Health Report, 2004: Changing HistoryWorld Health Organization2004 Available from: www.who.intAccessed October 5, 2014
- MathersCDLoncarDProjections of global mortality and burden of disease from 2002 to 2030PLoS Med2006311e44217132052
- CazzolaMPageCPCalzettaLMateraMGPharmacology and therapeutics of bronchodilatorsPharmacol Rev201264345050422611179
- Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseGlobal Initiative for Chronic Obstructive Lung Disease2014 Available from: http://www.goldcopd.org/Accessed October 5, 2014
- VogelmeierCKardosPHarariSGansSJStengleinSThirlwellJFormoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month studyRespir Med2008102111511152018804362
- VinckenWvan NoordJAGreefhorstAPDutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropiumEur Respir J200219220921611871363
- TashkinDPFergusonGTCombination bronchodilator therapy in the management of chronic obstructive pulmonaryRespir Res2013144923651244
- van der MolenTCazzolaMBeyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centered outcomesPrim Care Respir J201221110110822222945
- CazzolaMMolimardMThe scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPDPulm Pharmacol Ther20102325726720381630
- JayaramLWongCMcAuleyCReaHZengIO’DochartaighCCombined therapy with tiotropium and formoterol in chronic obstructive pulmonary disease: effect on 6-minute walk testCOPD2013101446647223875741
- AbramsonMCrockettAJDabscheckEon behalf of Lung Foundation Australia and the Thoracic Society of Australia and New ZealandThe COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease V2.38Brisbane2014
- National Clinical Guideline CentreChronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary CareLondonNational Clinical Guideline Centre2010
- QaseemAWiltTJWeibergerSEAmerican College of Physicians; American College of Chest Physicians; American Thoracic Society; European Respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American college of physicians, America college of chest physicians, America thoracic society and European Respiratory societyAnn Intern Med201115517919121810710
- Health CanadaSummary Basis of Decision (SBD) for Striverdi Respimat (Olodaterol Hydrochloride)2013 Available from: http://www.hc-sc.gc.ca/Accessed November 4, 2014
- Boehringer-ingelheim.com [homepage on the internet] c2010-14 [updated October 18, 2014 cited December 10, 2014]. Available from: www.boehringer-ingelheim.comAccessed December 12, 2014
- BouyssouTCasarosaPNalineEPharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical modelsJ Pharmacol Exp Ther20103341536220371707
- BrownSMBarnesPJDonnellyLEEffect of Olodaterol on the Relaxation of Small Airways [abstract]AmsterdamAnnual Congress of the European Respiratory Society2011
- AhmedatASWarnkenMJuergensURPaul PieperMRackéKThe long acting Beta2-adrenoceptor agonist olodaterol mediates inhibition of prepro-endothelin-1 expression in human lung fibroblastsAm J Respir Crit Care Med2011183A605
- CasarosaPKollakIKiechleTFunctional and biochemical rationales for the 24-hour-long duration of action of olodaterolJ Pharmacol Exp Ther2011337360060921357659
- FergusonGTFeldmanGJHofbauerPEfficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014962964524966672
- van NoordJASmeetsJJDrenthBM24-hour bronchodilation following a single dose of the novel β2-agonist olodaterol in COPDPulm Pharmacol Ther201124666667221839850
- van NoordJAKorduckiLHamiltonAKokerPFour weeks once daily treatment with BI 1744 CL, a novel long-acting β2-agonist, is effective in COPD patients [abstract]Am J Respir Crit Care Med2009179A6183
- JoosGAumannJLCoeckCKorduckiLHamiltonALvan NoordJComparison of 24-hour FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with COPD [abstract]Am J Respir Crit Care Med2012185A2930
- KochAPizzichiniEHamiltonALung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014969771425045258
- RoskellNSAnzuetoAHamiltonADisseBBeckerKOnce-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterolInt J Chron Obstruct Pulmon Dis2014981382425114521
- MaesenFPSmeetsJJSledsensTJWaldFDCornelissenPJTiotro-pium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study GroupEur Respir J19958150615138575576
- CoulsonFRFryerADMuscarinic acetylcholine receptors and airway diseasesPharmacol Ther200398596912667888
- van NoordJASmeetsJJCustersFLKorduckiLCornelissenPJPharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary diseaseEur Respir J20021963964411998992
- van NoordJABantjeTAElandMEKorduckiLCornelissenPJGA randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary diseaseThorax200255428929410722768
- CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J200219221722411866001
- TashkinDPCelliBSennSUPLIFT Study InvestigatorsA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
- KesteriSCasaburiRKukafkaDCopperCBImprovement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patientsInt J Chron Obstruct Pulmon Dis20083126136
- VogelmeierCHedererBGlaabTPOET-COPD InvestigatorsTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011364121093110321428765
- AnthonisenNRConnettJEEnrightPLManfredaJHospitalizations and mortality in the Lung Health StudyAm J Respir Crit Care Med2002166333333912153966
- DecramerMLChapmanKRDahlRINVIGORATE InvestigatorsOnce-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group studyLancet Respir Med20131752453324461613
- RodrigoGJNeffenHComparison of indacaterol with tiotropium or twice-daily long-acting beta-agonists for stable COPD: a systematic reviewChest20121421104111022383666
- KerwinEHébertJGallagherNEfficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 studyEur Respir J20124051106111423060624
- ChapmanKRBeehKMBeierJA blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 studyBMC Pulm Med2014141424438744
- BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
- MahlerDADecramerMD’UrzoADual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE studyEur Respir J20144361599160924176997
- WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
- DalePRCerneckaHSchmidtMThe pharmacological rationale for combining muscarinic receptor antagonists and beta-adrenoreceptor agonists in the treatment of airway and bladder diseaseCurr Opin Pharmacol201416314224682092
- CostaLRothMMiglinoNTiotropium sustains the anti-inflammatory action of olodaterol via the cyclic AMP pathwayPulm Pharmacol Ther201427293724269928
- BouyssouTCasarosaPPieperMSynergistic Bronchoprotective Activity of the Long-Acting Beta 2-Agonist Olodaterol with Tiotropium (Long-Acting M3 Antagonist) and Ciclesonide (Inhaled Steroid) on the Ovalbumin-Induced Bronchoconstriction in Anaesthetized Guinea Pigs [abstract]AmsterdamAnnual Congress of the European Respiratory Society2011
- BouyssouTSchnappACasarosaPPieperMPAddition of the new once-daily LABA BI 1744 to tiotropium results in superior bronchoprotection in pre-clinical models [abstract]Am J Respir Crit Care Med2010181A4445
- BrandPHedererBAustenGDewberryHMeyerTHigher lung deposition with Respimat Soft Mist Inhaler than HFA-MDI in COPD patients with poor techniqueInt J Chron Obstruct Pulmon Dis2008376377019281091
- SchürmannWSchmidtmannSMoroniPMasseyDQidanMRespimat® Soft Mist™ inhaler versus hydrofluoroalkane metered dose inhalerTreat Respir Med200541536115725050
- SinghSLokeYKFurbergCDInhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary diseaseJAMA2008300121439145018812535
- SinghSLokeYKEnrightPLFurbergCDMortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomized controlled trialsBMJ2011342d321521672999
- KarnerCChongJPoolePTiotropium versus placebo for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20127CD00928522786525
- GershonACroxfordRCalzavaraACardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary diseaseJAMA201317311751184
- BushAPavordIDTiotropium Respimat increases the risk of mortalityThorax20136868
- VerhammeKAfonsoARomioSStrickerBCBrusselleGGSturkenboomMCUse of tiotropium Respimat SMI versus tiotropium HandiHaler and mortality in patients with COPDEur Respir J20134260661523520322
- WiseRAAnzuetoACottonDTIOSPIR InvestigatorsTiotro-pium Respimat inhaler and the risk of death in COPDN Engl J Med2013369161491150123992515
- TashkinDMetzdorfNHallmanCKonen-BergmannMKupasKDahlRSafety of Tiotropium in Renally Impaired Patients [Abstract]Munich, GermanyEuropean Respiratory Society Annual Congress2014923
- BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J20154596997925573406
- MaltaisFBeckEWebsterDFour weeks once daily treatment with tiotropium + olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients [abstract]Eur Respir J201036suppl 541014s
- AalbersRMaleki-YazdiMRHamiltonADose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD [abstract]Eur Respir J2012402882S
- Boehringer IngelheimTOviTO™ Clinical Trial Programme2014 Available from: http://www.boehringer-ingelheim.comAccessed November 9, 2014
- BeehKMWestermanJKirstenAMThe 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary diseasePulm Pharmacol Ther201532535925956072
- clinicaltrials.gov [homepage on the internet]Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients ClinicalTrials.gov Identifier: NCT1969721; 2013 [updated December 11, 2014] Available from: https://clinicaltrials.gov/ct2/show/NCT1969721Accessed December 12, 2014
- clinicaltrials.gov [homepage on the internet]Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1) ClinicalTrials.gov Identifier: NCT1964352; 2013 [updated December 11, 2014]. Available from: https://clinicaltrials.gov/ct2/show/NCT1964352Accessed December 12, 2014
- clinicaltrials.gov [homepage on the internet]Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2) ClinicalTrials.gov Identifier: NCT2006732; 2013 [updated December 11, 2014]. Available from: https://clinicaltrials.gov/ct2/show/NCT2006732Accessed December 12, 2014
- MaltaisFIturriJGKirstenAP250 effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPDThorax201469suppl 2A186A187
- clinicaltrials.gov [homepage on the internet]Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients ClinicalTrials.gov Identifier: NCT1533922; 2012 [updated April 30, 2014]. Available from: https://clinicaltrials.gov/ct2/show/NCT201533922Accessed December 12, 2014
- clinicaltrials.gov [homepage on the internet]Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients ClinicalTrials.gov Identifier: NCT1533935; 2012 [updated April 30, 2014]. Available from: https://clinicaltrials.gov/ct2/show/NCT1533935Accessed December 12, 2014
- clinicaltrials.gov [homepage on the internet]To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways ClinicalTrials.gov Identifier: NCT2085161; 2014 [updated December 11, 2014]. Available from: https://clinicaltrials.gov/ct2/show/NCT2085161Accessed December 12, 2014
- Comparing the Efficacy of Tiotropium + Olodaterol (5/5 μg) Fixed Dose Combination (FDC) Over Tiotropium 5 μg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease ClinicalTrials.gov Identifier: NCT2296138; 2014 [updated December 11, 2014]. Available from: http://clinicaltrials.gov/ct2/show/NCT2296138Accessed December 12, 2014
- YuAPGuérinAPonce de LeonDTherapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalersJ Med Econ20111448649621679019
- AndersonPUse of Respimat® Soft Mist™ Inhaler in COPD patientsInt J Chron Obstruct Pulmon Dis20061325118046862
- GlaxoSmithKlineFDA Advisory Committee Briefing Document. ANOROTM ELLIPTATM (umeclidinium bromide/vilanterol inhalation powder) for treatment of chronic obstructive pulmonary disease. NDA 203975. Presented to Pulmonary-Allergy Drug Advisory Committee 2013 Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM367414.pdfAccessed December 7, 2014
- ZuWallackRAllenLHernandezGTingNAbrahamsREfficacy and safety of combining olodaterol Respimat® and tiotropium Handi-Haler® in patients with COPD: results of two randomized, double-blind, active-controlled studiesInt J COPD2014911331144